DURECT Corporation to Announce Q2 2024 Financial Results and Business Update

CUPERTINO, Calif., Aug. 7, 2024 -- DURECT Corporation, a biopharmaceutical company specializing in the development of epigenetic therapies, announced plans to release its second-quarter financial results on Tuesday, August 13, 2024. The management team will also conduct a conference call and webcast to discuss the financial outcomes and provide a corporate update at 4:30 pm Eastern Time. Details for accessing the call include guest dial-in numbers and a "Call me™" link for instant telephone access, which will be activated 15 minutes before the event.

DURECT Corporation focuses on creating innovative treatments for serious and life-threatening conditions. Their lead drug candidate, Larsucosterol, is designed to target and inhibit DNA methyltransferases (DNMTs), enzymes linked to hypermethylation seen in patients with alcohol-associated hepatitis (AH). Larsucosterol is currently undergoing clinical trials for AH treatment, and the U.S. Food and Drug Administration (FDA) has granted it Fast Track Designation, reflecting its potential to meet an unmet medical need.

In addition to Larsucosterol, DURECT has developed POSIMIR® (bupivacaine solution), a non-opioid analgesic for infiltration use. Utilizing the SABER® platform technology, POSIMIR® is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for marketing and distribution in the United States. This collaboration aims to provide effective pain management solutions without relying on opioids.

DURECT Corporation's dedication to epigenetic therapy development aims to revolutionize the treatment landscape for conditions like acute organ injury and cancer. The company's innovative approach focuses on correcting dysregulated DNA methylation processes, which play a significant role in the progression of these severe diseases.

DURECT Corporation emphasizes its commitment to advancing medical science and improving patient outcomes through cutting-edge research and development. The upcoming financial report and subsequent conference call will offer insights into the company's recent achievements and future plans, providing stakeholders with a clear understanding of its strategic direction and financial health.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!